Price complaints likely to be upheld in Greece
This article was originally published in SRA
Company objections to drug pricing levels given out by the Greek government in the September price bulletin are likely to be accepted, a senior Greek government official in the department in charge of drug reimbursement has told Regulatory Affairs Pharma's sister publication Scrip. At the same time, there have been new promises that the government – which has brought in a large number of austerity measures to deal with its global debt – will pay off its debt to pharmaceutical companies, which sits around €3 billion.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.